Chemerin-9 (149-157) TFA is a potent agonist of chemokine-like receptor 1 (CMKLR1). Chemerin-9 (149-157) TFA exhibits anti-inflammatory effect. Chemerin-9 (149-157) TFA stimulates the phosphorylation of Akt and ERK and the production of reactive oxygen species. Chemerin-9 (149-157) TFA improves Aβ1-42-induced memory impairment. Chemerin-9 (149-157) TFA regulates immune responses, adipocyte differentiation, and glucose metabolism.

Physicochemical Properties

Molecular Formula	C56H67F3N10O15
Molecular Weight	1177.18
Related CAS #	Chemerin-9 (149-157);676367-27-4
Appearance	Solid powder
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture.
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

ln Vitro	The phosphorylation of Akt and ERK, the generation of ROS, and the migration of cardiac fibroblasts are all stimulated by chemerin-9(149–157) TFA (0.1 nM; 24 hours) [4].
ln Vivo	In mice with PDM, chemerin-9 (149–157) TFA (0.2 mg/kg; i.p.; daily for 42 days) decreases glucose intolerance and IR [1]. In ApoE-/-mice, chemerin-9 (149–157) TFA (7.7 μg/kg; ih; daily for 28 days) suppresses inflammation and angiogenesis and shields the abdominal aorta from MMP damage [ 2]. Aβ1-42-induced memory impairment in male Kunming mice is ameliorated by Chemerin-9 (149-157) TFA (8 μg/kg; ICV; daily; for 14 days) [3].
Cell Assay	Western Blot Analysis[4] Cell Types: Cardiac fibroblasts Tested Concentrations: 0.1 nM Incubation Duration: 24 hrs (hours) Experimental Results: Stimulated phosphorylation of Akt and ERK.
Animal Protocol	Animal/Disease Models: PDM mice[1] Doses: 0.2 mg/kg Route of Administration: intraperitoneal (ip)injection; daily, for 42 days Experimental Results: Increased expression of chemerin, GLUT2, and PDX1, which led to the alleviation of glucose intolerance and IR in PDM model mice . Animal/Disease Models: ApoE-/- mice[2] Doses: 7.7 μg /kg Route of Administration: subcutaneous (sc) injection; daily, for 28 days Experimental Results: Suppressed the enlargement of abdominal aorta and reversed the SMC loss. Animal/Disease Models: ApoE-/- mice [2] Doses: 7.7 μg /kg Route of Administration: subcutaneous (sc) injection; daily, for 28 days Experimental Results: Down-regulated MMP2 and MMP-9 expression and diminished the levels of chemerin and CMKLR1. Animal/Disease Models: Male Kunming mice[3] Doses: 8 μg/kg Route of Administration: Intracerebroventrical injection; daily; for 14 days Experimental Results: Increased in the levels of pro-inflammatory cytokines such as interleukin-1β (IL-1β), tumor necrosis factor (TNF-α) and interleukin-6 (IL -6) in the hippocampus.
References	[1]. Regulatory effect of chemerin and therapeutic efficacy of chemerin 9 in pancreatogenic diabetes mellitus. Mol Med Rep. 2020 Mar;21(3):981-988. [2]. Chemerin-9 Attenuates Experimental Abdominal Aortic Aneurysm Formation in ApoE-/- Mice. J Oncol. 2021 Apr 17;2021:6629204. [3]. Chemerin-9 Peptide Enhances Memory and Ameliorates Aβ1-42-Induced Object Memory Impairment in Mice. Biol Pharm Bull. 2020 Feb 1;43(2):272-283. [4]. Chemerin-9 stimulates migration in rat cardiac fibroblasts in vitro. Eur J Pharmacol. 2021 Dec 5;912:174566.

Solubility Data

Solubility (In Vitro)

H2O :~100 mg/mL (~84.95 mM)

Solubility (In Vivo)

Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	0.8495 mL	4.2474 mL	8.4949 mL
	5 mM	0.1699 mL	0.8495 mL	1.6990 mL
	10 mM	0.0849 mL	0.4247 mL	0.8495 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.